Syngene International share price
NSE: SYNGENEBSE: 539268Healthcare ServicesSmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹372.50.
- Next results date: the board meets on 27 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹14,809 Cr359th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 29 Jul 2026
- 67.0
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹90 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 47.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 Apr 2026
- 3.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.34%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 29 Jul 2026
- 4.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹90 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 6.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 29 Jul 2026
- 7.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 Apr 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 4,44,23153.8% delivered
Results
Standalone, as consolidated accounts are on record for only 9 of the last ten years; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 29 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹663 Crdown 30.94%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹2.10 CrQuarter to Mar 2026: ₹148 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −0.3%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 24 Oct | Dec 2024Filed 23 Jan | Mar 2025Filed 12 Jun | Jun 2025Filed 23 Jul | Sep 2025Filed 5 Nov | Dec 2025Filed 22 Jan | Mar 2026Filed 29 Apr | Jun 2026Filed 29 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 821 | 877 | 948 | 799 | 830 | 834 | 960 | 663 |
| Net profit | 97 | 123 | 174 | 74 | 66 | 17 | 148 | −2 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 11.8% | 14.0% | 18.4% | 9.3% | 8.0% | 2.0% | 15.4% | −0.3% |
Business segments
In the year to Mar 2026 the company reports one business segment, Contract Research and Manufacturing Services, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 41% of 2,480 trading days over the last 10 years.
At or below today's level on 0.4% of 1,981 trading days since Oct 2018.
At or below today's level on 3% of 1,981 trading days since Oct 2018.
At or below today's level on 99.7% of 2,480 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −46.0% | −34.9% | −17.6% | 0.3% |
| 3 years | −12.9% | −13.7% | +0.7% | 0.2% |
| 5 years | −6.2% | −5.7% | −0.8% | 0.2% |
Mutual funds holding it
120 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 51 of the 64 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 5
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 31
- CutCut. Funds that held fewer shares than at the end of the month before.
- 33
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 49
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 7
| Fund | |||
|---|---|---|---|
 Nippon India Small Cap FundNippon India Mutual Fund | 1,33,22,540 | 0.60% | ₹486.7 Cr |
 ICICI Prudential Multi Cap FundICICI Prudential Mutual Fund | 79,50,848 | 1.55% | ₹290.4 Cr |
 SBI Multi Asset Allocation FundSBI Mutual Fund | 70,00,000 | 1.22% | ₹255.7 Cr |
| Nippon India Multi Cap FundNippon India Mutual Fund | 65,81,205 | 0.45% | ₹240.4 Cr |
| ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 65,78,033 | 3.50% | ₹240.3 Cr |
| Nippon India Focused FundNippon India Mutual Fund | 59,96,046 | 2.71% | ₹219.0 Cr |
 DSP ELSS Tax Saver FundDSP Mutual Fund | 39,03,263 | 0.92% | ₹142.6 Cr |
| ICICI Prudential ELSS - Tax Saver FundICICI Prudential Mutual Fund | 37,70,138 | 1.02% | ₹137.7 Cr |
| DSP Large & Mid Cap FundDSP Mutual Fund | 35,35,665 | 0.75% | ₹129.2 Cr |
| Nippon India Pharma FundNippon India Mutual Fund | 35,01,497 | 1.40% | ₹127.9 Cr |
Peers and competitors
Healthcare Research, Analytics & Technology, 11 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Syngene International in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 IndegeneINDGN | 13,781 | 34.4 | 4.4 | 21.0 | +30.4% | −7.9% | 13.9% | 15.6% | 0.39% |
 Suven Life SciencesSUVEN | 7,385 | – | – | – | +17.3% | – | −100.5% | −63.0% | 0.00% |
 Vimta LabsVIMTALABS | 2,092 | 26.3 | 4.6 | 14.0 | +15.2% | – | 19.1% | 21.4% | 0.43% |
 BilcareBI | 197 | – | 1.0 | 11.5 | −0.9% | – | – | 5.4% | 0.00% |
 Novelix PharmaceuticalsNOVELIX | 170 | 46.7 | – | – | +179.9% | – | 11.3% | 8.7% | 0.00% |
 Jeevan Scientific TechnologyJSTL | 163 | – | 2.3 | 11.7 | +66.1% | – | – | 8.8% | 0.00% |
 TAKETAKE | 162 | 12.6 | 5.2 | – | – | −68.2% | 49.8% | −5.6% | 0.00% |
 GlobalSpace Technologies540654 | 82 | – | 1.4 | 12.0 | +37.2% | – | – | 7.5% | 0.00% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 25 Jun 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.25 |
| 27 Jun 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.25 |
| 28 Jun 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.25 |
| 30 Jun 2023 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.50 |
| 30 Jun 2023 | Special | ₹0.75 |
| 30 Jun 2022 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.50 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
17 Oct · Analysts
Sep 2026
24 Sep · General Updates
21 Sep · Management
21 Sep · Analysts
Syngene International share price by year
Each calendar year to 2025.Syngene International share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 651.00 | −24.2% | 879.25 | 609.45 |
| 2024 | 858.45 | +22.4% | 947.80 | 652.00 |
| 2023 | 701.45 | +19.8% | 843.55 | 550.95 |
| 2022 | 585.55 | −5.5% | 663.60 | 526.65 |
| 2021 | 619.90 | −3.1% | 670.00 | 500.70 |
| 2020 | 639.60 | +99.8% | 639.60 | 222.70 |
| 2019 | 320.15 | +14.3% | 352.05 | 270.15 |
| 2018 | 280.10 | +3.5% | 339.60 | 262.60 |
| 2017 | 270.68 | −3.6% | 303.98 | 218.90 |
| 2016 | 280.93 | +34.9% | 317.13 | 175.18 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 370.00 | 373.25 | 361.60 | 366.85 | 366.26 | 4,44,231 | 53.8% |
| 22 Oct 2026 | 372.75 | 378.60 | 366.70 | 372.50 | 372.70 | 4,48,590 | 54.0% |
| 21 Oct 2026 | 394.15 | 405.40 | 374.10 | 376.45 | 383.79 | 5,69,207 | 54.0% |
| 19 Oct 2026 | 382.50 | 402.00 | 382.50 | 397.50 | 393.95 | 17,09,879 | 45.5% |
| 16 Oct 2026 | 385.00 | 390.00 | 382.50 | 386.10 | 385.96 | 3,58,384 | 49.2% |
| 15 Oct 2026 | 390.55 | 397.90 | 382.40 | 384.20 | 388.80 | 8,47,215 | 51.1% |
| 14 Oct 2026 | 382.00 | 394.15 | 378.25 | 390.50 | 389.65 | 10,02,583 | 52.2% |
| 13 Oct 2026 | 374.05 | 381.00 | 366.15 | 379.55 | 374.91 | 6,33,750 | 40.7% |
| 12 Oct 2026 | 358.50 | 376.80 | 353.95 | 371.95 | 368.46 | 37,10,843 | 22.3% |
| 9 Oct 2026 | 346.10 | 351.95 | 344.45 | 347.40 | 348.34 | 3,79,586 | 64.8% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 11 Jun 2019 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
About Syngene International
Syngene International Limited is a contract research, development and manufacturing organisation. It offers a one-stop platform for drug discovery, development and manufacturing. Its capabilities span small molecules, peptides, biologics, antibody-drug conjugates and oligonucleotides. It works with large, mid-sized and emerging biopharma companies, and also with customers in animal health, consumer goods and specialty chemicals. It has about 400 active customers.
The business runs through four divisions: Discovery Services, Translational & Clinical Research, Dedicated Centers, and Contract Development and Manufacturing Services. Dedicated Centers give an individual client ring-fenced infrastructure for exclusive operations. The manufacturing division has a small molecule business and a large molecule business, the latter covering process development and manufacturing of clinical and commercial supplies.
The company is headquartered in Bengaluru, where its main campus for research, development and manufacturing stands. It also has an R&D centre in Genome Valley, Hyderabad, an API manufacturing facility in Mangaluru, and a biologics manufacturing facility at Bayview, Maryland, USA. It has commercial teams in the United Kingdom and Europe. It had 8,373 employees on 31 March 2026.
It was incorporated in 1993 and has been listed on the stock exchanges since 2015. Its history includes the merger of Clinigene, the acquisition of a multi-modal biologics facility from Stelis Biopharma Ltd, and the acquisition of its first biologics site in the USA from Emergent Manufacturing Operations Baltimore, LLC.
Syngene is an operationally independent, publicly listed subsidiary of Biocon Limited, a company founded in 1978.
- Legal name
- Syngene International Limited
- NSE symbol
- SYNGENE
- BSE code
- 539268
- ISIN
- INE398R01022
- Industry
- Healthcare Services
- Listed
- Aug 2015
- Face value
- ₹10
- CIN
- L85110KA1993PLC014937
- Corporate identity number, the registrar of companies' code for it